Perhaps the buoyancy in the SP is being driven by the other...

Perhaps the buoyancy in the SP is being driven by the other companies (Viralytics, RHS etc etc) recent deals. I'd say that potential buyers are probably happy to wait for PhII data to come in on PTSD (in other words, there isn't going to be a frenzy before then). Merck's DD on BNO will also be streets ahead of anyone else. Merck knows what they are dealing with and they know who they are dealing with. That could mean a quick decision (by Merck) when the time comes. That, of course, hinges on a positive trial result. In the meantime, I'll sit back and enjoy the higher SP. GLTA